Why is Mangalam Drugs falling/rising?

Persistent Downward Momentum Reflects in Price and Returns

The stock closed at ₹24.05, down by ₹0.24 or 0.99% as of 08:33 PM on 19-Dec, edging closer to its 52-week low of ₹23.77, just 1.16% away. This recent fall is part of a broader negative trend, with the share price having declined by 4.79% over the past week. This contrasts sharply with the Sensex, which recorded a marginal decline of 0.40% in the same period, highlighting Mangalam Drugs’ relative weakness.

Over longer horizons, the underperformance is even more pronounced. The stock has plummeted by 55.96% in the last month and an alarming 79.26% year-to-date, while the Sensex has gained 8.69% over the same timeframe. The one-year and three-year returns for Mangalam Drugs are similarly dismal, with losses exceeding 79% and 82% respectively, whereas the Sensex has posted positive returns of 7.21% and 37.41% over these periods. Even over five years, the stock remains down by over 82%, in stark contrast to the Sensex’s robust 80.85% gain.

Technical Indicators Signal Continued Weakness

From a technical perspective, Mangalam Drugs is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment suggests a bearish trend with no immediate signs of reversal. The stock’s inability to sustain levels above these averages typically signals persistent selling pressure and a lack of buying interest from market participants.

Moreover, the stock has been on a consecutive five-day losing streak, reinforcing the negative momentum. This sustained decline indicates that investors remain cautious or pessimistic about the company’s near-term prospects.

Declining Investor Participation and Liquidity Concerns

Investor participation appears to be waning, as evidenced by a significant drop in delivery volume. On 18 Dec, the delivery volume stood at 30,050 shares, marking a 35.27% decrease compared to the five-day average delivery volume. Reduced delivery volumes often reflect diminished conviction among investors, potentially signalling a lack of confidence or interest in accumulating the stock at current levels.

Liquidity remains adequate for trading, with the stock’s traded value supporting reasonable trade sizes. However, the declining volume trend could impact price stability and widen bid-ask spreads, further deterring active participation.

Sector and Market Context

On the day in question, Mangalam Drugs underperformed its sector by 1.74%, indicating that the weakness is not isolated to the broader pharmaceutical or organic chemicals space but is more acute for this particular stock. While the sector may be facing headwinds, Mangalam Drugs’ sharper decline suggests company-specific challenges or investor concerns that are weighing heavily on its valuation.

Given the stark contrast between the stock’s performance and the broader market indices, it is clear that Mangalam Drugs is struggling to regain investor confidence. The persistent downtrend, proximity to 52-week lows, and subdued trading volumes collectively point to a cautious market stance.

Outlook for Investors

Investors should approach Mangalam Drugs with caution given the sustained negative price action and weak technical signals. The stock’s significant underperformance relative to the Sensex and sector peers over multiple timeframes underscores the challenges it faces. Until there is a clear catalyst or improvement in fundamentals, the prevailing trend suggests continued pressure on the share price.

Market participants may wish to monitor volume trends and moving averages closely for any signs of reversal or stabilisation. Meanwhile, exploring alternative investment opportunities within the pharmaceuticals and biotechnology sectors could be prudent for those seeking exposure to this space with potentially better risk-reward profiles.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →